Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA, is a prominent player in the global pharmaceutical industry, headquartered in the United States. Founded in 2001, the company has established a strong presence in key operational regions, including North America and Europe, focusing on the development and manufacturing of innovative medicines. Specialising in a diverse range of therapeutic areas such as dermatology, respiratory, and oncology, Glenmark is recognised for its commitment to research and development, which has led to the introduction of unique generic and specialty pharmaceuticals. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of new therapies, solidifying its market position as a trusted provider of high-quality healthcare solutions.
DitchCarbon Score
How does Glenmark Pharmaceuticals Inc., USA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Pharmaceuticals Inc., USA's score of 35 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glenmark Pharmaceuticals Inc., USA's reported carbon emissions
Glenmark Pharmaceuticals Inc., USA, currently does not have available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives related to climate commitments. Without specific emissions figures or defined goals, it is challenging to assess their current environmental impact or progress in reducing carbon emissions. The absence of documented reduction initiatives suggests that Glenmark may still be in the early stages of formalising its climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for Glenmark to establish clear commitments and measurable targets to align with global climate action efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glenmark Pharmaceuticals Inc., USA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
